Federal Register / Vol. 86, No. 123 / Wednesday, June 30, 2021 / Notices 34771 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 4120, MSC 7802, 

Bethesda, MD 20892, (301) 806–7314, 

shahb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Virology. 

Date: July 28, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Marci Scidmore, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3192, 

MSC 7808, Bethesda, MD 20892, 301–435– 

1149, marci.scidmore@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: HIV Molecular Virology, Cell 

Biology, Immune and Therapeutic-Focused 

Application. 

Date: July 28, 2021. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Audrey O. Lau, MPH, 

Ph.D., Chief Center for Scientific Review, 

6701 Rockledge Drive, Bethesda, MD 20892, 

(301) 594–4088, audrey.lau@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Endocrinology, Metabolism, 

Nutrition and Reproductive Sciences. 

Date: July 28, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elaine Sierra-Rivera, Ph.D., 

IRG Chief, EMNR IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 6182, MSC 7892, 

Bethesda, MD 20892, 301–435–2514, 

riverase@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Social Sciences and Chronic and 

Infectious Disease Epidemiology. 

Date: July 28, 2021. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lisa Steele, Ph.D., 

Scientific Review Officer, PSE IRG, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

MSC 7770, Bethesda, MD 20892, 301–594– 

6594, steeleln@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Social 

Sciences and Chronic and Infectious Disease 

Epidemiology. 

Date: July 28, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Denise Wiesch, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3138, 

MSC 7770, Bethesda, MD 20892, (301) 437– 

3478, wieschd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; UNITE 

Transformative Research to Address Health 

Disparities and Advance Health Equity at 

Minority Serving Institutions (U01). 

Date: July 29–30, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aruna K. Behera, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4211, 

MSC 7814, Bethesda, MD 20892, 301–435– 

6809, beheraak@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Mycology, Parasitology 

and Pathogenesis. 

Date: July 29, 2021. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kenneth M. Izumi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3204, 

MSC 7808, Bethesda, MD 20892, 301–496– 

6980, izumikm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Endocrinology and 

Metabolism. 

Date: July 29, 2021. 

Time: 10:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Liliana N. Berti-Mattera, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, RM 6158, 

MSC 7890, Bethesda, MD 20892, (301) 827– 

7609, liliana.berti-mattera@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Endocannabinoids as Therapeutic 

Targets. 

Date: July 29, 2021. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Peter B. Guthrie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4142, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

1239, guthriep@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Innate and Adaptive Immunology. 

Date: July 30, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kenneth A. Roebuck, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5214, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1166, roebuckk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Innate and Adaptive Immunology. 

Date: July 30, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Neerja Kaushik-Basu, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3198, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

1742, kaushikbasun@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 24, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13942 Filed 6–29–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Scientific Advisory Committee on 

Alternative Toxicological Methods; 

Announcement of Meeting; Request 

for Comments 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

next meeting of the Scientific Advisory 

Committee on Alternative Toxicological 

Methods (SACATM). SACATM is a 

federally chartered external advisory 

group of scientists from the public and 

private sectors, including 


jbell on DSKJLSW7X2PROD with NOTICES
34772 Federal Register / Vol. 86, No. 123 / Wednesday, June 30, 2021 / Notices 

representatives of regulated industry 

and national animal protection 

organizations. SACATM advises the 

Interagency Coordinating Committee on 

the Validation of Alternative Methods 

(ICCVAM), the National Toxicology 

Program (NTP) Interagency Center for 

the Evaluation of Alternative 

Toxicological Methods (NICEATM), and 

the Director of the National Institute of 

Environmental Health Sciences (NIEHS) 

and NTP regarding statutorily mandated 

duties of ICCVAM and activities of 

NICEATM. This SACATM meeting will 

be a virtual meeting only and available 

to the public for remote viewing. 

Registration is required to access the 

virtual meeting and to present oral 

comments. Information about the 

meeting and registration are available at 

https://ntp.niehs.nih.gov/go/32822. 

DATES:

Meeting: September 28, 2021, 10:00 

a.m.–3:30 p.m. EDT; September 29, 

2021, 10:00 a.m.–4:00 p.m. EDT. Ending 

times are approximate; meeting may end 

earlier or run later. 

Registration for Virtual Meeting: 

Deadline is September 29, 2021, 4:00 

p.m. EDT. 

Written Public Comment 

Submissions: Deadline is September 17, 

2021. 

Register to Present Oral Comments: 

Deadline is September 17, 2021. 

Registration to view the virtual 

meeting and present oral public 

comments is required. 

ADDRESSES:

Meeting web page: The preliminary 

agenda, registration, and other meeting 

materials are at https://

ntp.niehs.nih.gov/go/32822. 

Virtual Meeting: The URL for viewing 

the virtual meeting will be provided to 

those who register for viewing. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Sheena Scruggs, Designated Federal 

Official for SACATM, Office of Policy, 

Review, and Outreach, Division of NTP, 

NIEHS, P.O. Box 12233, K2–03, 

Research Triangle Park, NC 27709. 

Phone: 984–287–3355, Email: 

sheena.scruggs@nih.gov. Hand Deliver/ 

Courier address: 530 Davis Drive, Room 

K2126, Morrisville, NC 27560. 

SUPPLEMENTARY INFORMATION: 

Meeting and Registration: The 

meeting is open to the public with time 

scheduled for oral public comments. 

Due to restrictions on in-person 

gatherings amid ongoing public health 

concerns, the meeting will be convened 

as a virtual meeting. 

SACATM will provide input to 

ICCVAM, NICEATM, and NIEHS on 

programmatic activities and issues. 

Preliminary agenda items for the 

upcoming meeting include: (1) Major 

ICCVAM accomplishments in 2021; (2) 

regulatory needs and research 

applications for ecotoxicity testing; (3) 

evolving approaches to validation; and 

(4) update on NICEATM computational 

resources. Please see the preliminary 

agenda for information about specific 

presentations. 

The preliminary agenda, roster of 

SACATM members, background 

materials, public comments, and any 

additional information will be posted 

when available on the SACATM 

meeting website (https://

ntp.niehs.nih.gov/go/32822) or may be 

requested in hardcopy from the 

Designated Federal Official for 

SACATM. Following the meeting, 

summary minutes will be prepared and 

made available on the SACATM 

meeting website. 

Registration is required to attend the 

virtual meeting and is open to all 

interested persons. Registrants will 

receive instructions on how to access 

the virtual meeting in the email 

confirming their registration. 

Individuals who plan to provide oral 

comments (see below) are required to 

register online at the SACATM meeting 

website (https://ntp.niehs.nih.gov/go/ 

32822) by September 17, 2021, to 

facilitate planning for the meeting. 

Individuals are encouraged to visit the 

website often to stay abreast of the most 

current information regarding the 

meeting. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify Ms. Robbin Guy at phone: (984) 

287–3136 or email: robbin.guy@nih.gov 

in advance of the meeting. TTY users 

should contact the Federal TTY Relay 

Service at 800–877–8339. Requests 

should be made at least five business 

days in advance of the event. 

Written Public Comments: Written 

and oral public comments are invited 

for the agenda topics. Guidelines for 

public comments are available at 

https://ntp.niehs.nih.gov/ntp/about_

ntp/guidelines_public_comments_

508.pdf. The deadline for submission of 

written comments is September 17, 

2021. Written public comments should 

be submitted through the meeting 

website. Persons submitting written 

comments should include name, 

affiliation, mailing address, phone, 

email, and sponsoring organization (if 

any). Written comments received in 

response to this notice will be posted on 

the NTP website, and the submitter will 

be identified by name, affiliation, and 

sponsoring organization (if any). 

Oral Public Comment Registration: 

The preliminary agenda allows for 

several public comment periods, each 

allowing up to six commenters a 

maximum of five minutes per speaker. 

Registration for oral comments is on or 

before September 17, 2021, at https://

ntp.niehs.nih.gov/go/32822. Registration 

is on a first-come, first-served basis. 

Each organization is allowed one time 

slot per comment period. After the 

maximum number of speakers per 

comment period is exceeded, 

individuals registering to submit an oral 

comment for the topic will be placed on 

a wait list and notified should an 

opening become available. Commenters 

will be notified after September 17, 

2021, to provide logistical information 

for their presentations. If possible, oral 

public commenters should send a copy 

of their slides and/or statement or 

talking points to Robbin Guy by email: 

guyr2@niehs.nih.gov by September 17, 

2021. 

Meeting Materials: The preliminary 

meeting agenda will be posted when 

available on the meeting web page at 

https://ntp.niehs.nih.gov/go/32822 and 

will be updated one week before the 

meeting. Individuals are encouraged to 

visit this web page often to stay abreast 

of the most current information 

regarding the meeting. 

Responses to this notice are 

voluntary. No proprietary, classified, 

confidential, or sensitive information 

should be included in statements 

submitted in response to this notice or 

presented during the meeting. This 

request for input is for planning 

purposes only and is not a solicitation 

for applications or an obligation on the 

part of the U.S. Government to provide 

support for any ideas identified in 

response to the request. Please note that 

the U.S. Government will not pay for 

the preparation of any information 

submitted or for its use of that 

information. 

Background Information on ICCVAM, 

NICEATM, and SACATM: ICCVAM is 

an interagency committee composed of 

representatives from 17 federal 

regulatory and research agencies that 

require, use, generate, or disseminate 

toxicological and safety testing 

information. ICCVAM conducts 

technical evaluations of new, revised, 

and alternative safety testing methods 

and integrated testing strategies with 

regulatory applicability, and promotes 

the scientific validation and regulatory 

acceptance of testing methods that more 

accurately assess the safety and hazards 

of chemicals and products and replace, 

reduce, or refine (enhance animal wellbeing and lessen or avoid pain and 

distress) animal use. 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 123 / Wednesday, June 30, 2021 / Notices 34773 

1Prior to 2002, the NSDUH was referred to as the 

National Household Survey on Drug Abuse 

(NHSDA). 

The ICCVAM Authorization Act of 

2000 (42 U.S.C. 285l–3) establishes 

ICCVAM as a permanent interagency 

committee of NIEHS and provides the 

authority for ICCVAM involvement in 

activities relevant to the development of 

alternative test methods. Additional 

information about ICCVAM can be 

found at http://ntp.niehs.nih.gov/go/ 

iccvam. 

NICEATM administers ICCVAM, 

provides scientific and operational 

support for ICCVAM-related activities, 

and conducts and publishes analyses 

and evaluations of data from new, 

revised, and alternative testing 

approaches. NICEATM and ICCVAM 

work collaboratively to evaluate new 

and improved testing approaches 

applicable to the needs of U.S. federal 

agencies. NICEATM and ICCVAM 

welcome the public nomination of new, 

revised, and alternative test methods 

and strategies for validation studies and 

technical evaluations. Additional 

information about NICEATM can be 

found at http://ntp.niehs.nih.gov/go/ 

niceatm. 

SACATM, established by the ICCVAM 

Authorization Act [Section 285l–3(d)], 

provides advice on priorities and 

activities related to the development, 

validation, scientific review, regulatory 

acceptance, implementation, and 

national and international 

harmonization of new, revised, and 

alternative toxicological test methods to 

ICCVAM, NICEATM, and Director of 

NIEHS and NTP. Additional 

information about SACATM, including 

the charter, roster, and records of past 

meetings, can be found at http://

ntp.niehs.nih.gov/go/167. 

Dated: June 24, 2021. 

Brian R. Berridge, 

Associate Director, National Toxicology 

Program. 

[FR Doc. 2021–13919 Filed 6–29–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer at (240) 276–0361. 

Project: 2022 National Survey on Drug 

Use and Health (OMB No. 0930–0110) 

SAMHSA is requesting from the 

Office of Management and Budget 

(OMB) approval to administer the 

National Survey on Drug Use and 

Health (NSDUH), a survey of the U.S. 

civilian, non-institutionalized 

population aged 12 years old or older. 

NSDUH data are used to determine the 

prevalence of use of tobacco products, 

alcohol, illicit substances, and illicit use 

of prescription drugs. The results are 

used by SAMHSA, the Office of 

National Drug Control Policy (ONDCP), 

federal government agencies, and other 

organizations and researchers to 

establish policy, direct program 

activities, and better allocate resources. 

As certain parts of the United States 

reduce COVID–19 restrictions, NSDUH 

in-person data collection will proceed 

where possible. However, to ensure 

sufficient data are collected to produce 

nationally representative estimates for 

the 2022 survey, NSDUH will continue 

to employ a mix of in-person and webbased modes of administration to allow 

those respondents living in areas with 

COVID–19 restrictions the opportunity 

to participate. If the COVID–19 

pandemic subsides to such levels to 

allow in-person data collection to 

resume nationwide, SAMHSA may 

reassess that multimode data collection 

model as part of the 2022 NSDUH. 

In those areas where in-person data 

collection is permitted, NSDUH 

protocols, processes, and materials will 

continue to reflect the need to ensure 

the safety of respondents and field 

interviewers with respect to COVID– 

19—after initial implementation of such 

measures beginning in October 2020— 

which include equipping field 

interviewers with masks, gloves, 

disinfecting wipes, and hand sanitizer 

for use during data collection and 

providing a COVID–19 risk information 

form to all respondents. 

Unlike previous NSDUHs, a hybrid 

address-based sampling (ABS) design 

will be implemented for the 2022 

NSDUH. ABS refers to the sampling of 

residential addresses from a list based 

on the U.S. Postal Service’s 

Computerized Delivery Sequence file. In 

areas with high expected ABS coverage, 

the ABS frame will be used. In all other 

areas, traditional field enumeration will 

be used to construct the dwelling unit 

frames. 

In addition, the NSDUH questionnaire 

must be updated periodically to reflect 

changing substance use and mental 

health issues and to continue producing 

current data. For the 2022 NSDUH, the 

following questionnaire updates are 

planned: (1) Replacing the tobacco 

module with a redesigned nicotine 

module that includes questions about 

vaping, removes low priority items to 

reduce respondent burden and 

eliminates outdated terminology; (2) 

revising the marijuana module to 

include questions about the use of CBD, 

update questions on the mode of 

administration and eliminate outdated 

terminology and includes changes to the 

market information for marijuana 

questions; (3) redesigning the adult and 

youth mental health services utilization 

modules into one Mental Health Service 

Utilization model to remove questions 

with outdated terminology and include 

questions about newer treatments with 

recent increases in popularity; and (4) 

replacing the drug treatment module 

with a redesigned alcohol and drug 

treatment module that includes 

questions about newer treatments and 

those that have increased in popularity, 

as well as eliminating outdated 

terminology and reducing respondent 

burden. 

As with all NSDUH/NHSDA 1 surveys 

conducted since 1999, the sample size 

of the NSDUH main study for 2022 will 

be sufficient to permit prevalence 

estimates for each of the fifty states and 

the District of Columbia. The total 

annual burden estimate for the NSDUH 

main study is shown below in Table 1. 


jbell on DSKJLSW7X2PROD with NOTICES